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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 is the third in this series of biennial publications. This version provides concise overviews of the key properties of nearly 1800 human drug targets with an
emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of
target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13882/full.
In addition to this overview, in which are identified ‘Other protein targets’ which fall outside of the subsequent categorisation, there are eight areas of focus: G protein-coupled receptors, ligand-gated
ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary
information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of
related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in
close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human
drug targets, where appropriate.
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Introduction
In order to allow clarity and consistency in pharmacology, there is
a need for a comprehensive organisation and presentation of the
targets of drugs. This is the philosophy of the IUPHAR/BPS Guide
to PHARMACOLOGY presented on the online free access database
(http://www.guidetopharmacology.org/). This database is sup-
ported by the British Pharmacological Society (BPS), the Interna-
tional Union of Basic and Clinical Pharmacology (IUPHAR), the
University of Edinburgh and previously the Wellcome Trust. Data
included in the Guide to PHARMACOLOGY are derived in large
part from interactions with the subcommittees of the Nomencla-
ture Committee of the International Union of Basic and Clinical
Pharmacology (NC-IUPHAR). A major influence on the develop-
ment of the database was Tony Harmar (1951-2014), who worked
with a passion to establish the curators as a team of highly in-
formed and informative individuals, with a focus on high-quality
data input, ensuring a suitably validated dataset. The Editors of
the Concise Guide have compiled the individual records, in con-
cert with the team of Curators, drawing on the expert knowl-
edge of these latter subcommittees. The tables allow an indication
of the status of the nomenclature for the group of targets listed,
usually previously published in Pharmacological Reviews. In the
absence of an established subcommittee, advice from several
prominent, independent experts has generally been obtained to
produce an authoritative consensus on nomenclature, which at-
tempts to fit in within the general guidelines from NC-IUPHAR.
This current edition, the Concise Guide to PHARMACOLOGY
2017/18, is the latest snapshot of the database in print form, fol-
lowing on from the Concise Guide to PHARMACOLOGY 2015/16.
It contains data drawn from the online database as a rapid
overview of the major pharmacological targets. Thus, there are
many fewer targets presented in the Concise Guide compared to
the online database. The priority for inclusion in the Concise
Guide is the presence of quantitative pharmacological data. This
means that often orphan family members are not presented in the
Concise Guide, although structural information is available on the
online database. The organisation of the data is tabular (where ap-
propriate) with a standardised format, where possible on a single
page, intended to aid understanding of, and comparison within, a
particular target group. The Concise Guide is intended as an initial
resource, with links to additional reviews and resources for greater
depth and information. Pharmacological and structural data focus
primarily on human gene products, wherever possible, with links
to HGNC gene nomenclature and UniProt IDs. In a few cases,
where data from human proteins are limited, data from other
species are indicated. Pharmacological tools listed are prioritised
on the basis of selectivity and availability. That is, agents (agonists,
antagonists, inhibitors, activators, etc.) are included where they
are both available (by donation or from commercial sources, now
or in the near future) AND the most selective. The Concise Guide
is divided into nine sections, which comprise pharmacological tar-
gets of similar structure/function. These are G protein-coupled
receptors, ligand-gated ion channels, voltage-gated ion channels,
other ion channels, catalytic receptors, nuclear hormone recep-
tors, enzymes, transporters and other protein targets. We hope
that the Concise Guide will provide for researchers, teachers and
students a state-of-the art source of accurate, curated information
on the background to their work that they will use in the Introduc-
tions to their Research Papers or Reviews, or in supporting their
teaching and studies. We recommend that any citations to in-
formation in the Concise Guide are presented in the following
format:
Alexander SPH et al. (2017). The Concise Guide to PHARMACOL-
OGY 2017/18: Overview. Br J Pharmacol 174: S1–S16.
In this overview are listed protein targets of pharmacological inter-
est, which are not G protein-coupled receptors, ligand-gated ion
channels, voltage-gated ion channels, ion channels, nuclear hor-
mone receptors, catalytic receptors, transporters or enzymes.
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Other Protein Targets
Family structure
S6 Adiponectin receptors
– B-cell lymphoma 2 (Bcl-2) protein family
S7 Blood coagulation components
– Bromodomain-containing proteins
S7 Non-enzymatic BRD containing proteins
S8 Carrier proteins
S9 CD molecules
– Chromatin-interacting transcriptional repressors
S10 Methyllysine reader proteins
– Circadian clock proteins
– Claudins
– EF-hand domain containing
S11 Fatty acid-binding proteins
– G-alpha family G(q) subfamily
– Heat shock proteins
– Immunoglobulins
– Inhibitors of apoptosis (IAP) protein family
– Kelch-like proteins
– Kinesins
– Leucine-rich repeat proteins
– Lymphocyte antigens
– Mitochondrial-associated proteins
– Myosin binding proteins
– Non-catalytic pattern recognition receptors
– Absent in melanoma (AIM)-like receptors (ALRs)
– C-type lectin-like receptors (CLRs)
– Other pattern recognition receptors
S12 Notch receptors
– Pentaxins
– Serum pentaxins
S13 Regulators of G protein Signaling (RGS) proteins
S14 R4 family
– Repulsive guidance molecules
– Reticulons and associated proteins
– Ribosomal factors
S14 Sigma receptors
S15 Tubulins
– Tumour-associated proteins
– WD repeat-containing proteins
Adiponectin receptors
Other protein targets → Adiponectin receptors
Overview: Adiponectin receptors (provisional nomen-
clature, ENSFM00500000270960) respond to the 30 kDa
complement-related protein hormone adiponectin (also known
as ADIPOQ: adipocyte, C1q and collagen domain-containing
protein; ACRP30, adipose most abundant gene transcript 1;
apM-1; gelatin-binding protein: Q15848) originally cloned from
adipocytes [49]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [90]. Signalling through these receptors
appears to avoid G proteins; modelling based on the crystal struc-
tures of the adiponectin receptors suggested ceramidase acivity,
which would make these the first in a new family of catalytic re-
ceptors [93].
Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin (ADIPOQ, Q15848) > adiponectin (ADIPOQ, Q15848) globular adiponectin (ADIPOQ, Q15848) = adiponectin (ADIPOQ, Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [33].
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Further reading on Adiponectin receptors
Fisman EZ et al. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, dia-
betes, and coronary disease? Cardiovasc Diabetol 13: 103 [PMID:24957699]
Matsuda M et al. (2014) Roles of adiponectin and oxidative stress in obesity-associated metabolic
and cardiovascular diseases. Rev Endocr Metab Disord 15: 1-10 [PMID:24026768]
Ruan H et al. (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:
101-9 [PMID:26993044]
Wang Y et al. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Re-
ceptor Modification. Trends Endocrinol Metab 28: 519-530 [PMID:28473178]
Zhao L et al. (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends
Cardiovasc Med 24: 319-24 [PMID:25220977]
Blood coagulation components
Other protein targets → Blood coagulation components
Overview: Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation,
adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms
from less active precursors, typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.
Nomenclature coagulation factor V coagulation factor VIII serpin family C member 1
HGNC, UniProt F5, P12259 F8, P00451 SERPINC1, P01008
Selective activators – – heparin (pKd 7.8) [26], fondaparinux (pKd 7.5) [62], dalteparin [32], danaparoid
[16, 56], enoxaparin [19], tinzaparin [20]
Selective inhibitors drotrecogin alfa [36, 37] drotrecogin alfa [36, 37] –
Further reading on Blood coagulation components
Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-51
[PMID:25712994]
Girolami A et al. (2017) New clotting disorders that cast new light on blood coagulation and may
play a role in clinical practice. J Thromb Thrombolysis 44: 71-75 [PMID:28251495]
Rana K et al. (2016) Blood flow and mass transfer regulation of coagulation. Blood Rev 30: 357-68
[PMID:27133256]
Searchable database: http://www.guidetopharmacology.org/index.jsp Blood coagulation components S7
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Non-enzymatic BRD containing proteins
Other protein targets → Bromodomain-containing proteins → Non-enzymatic BRD containing proteins
Overview: Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufficient pharmacology exists.
Nomenclature bromodomain adjacent
to zinc finger domain 2A
bromodomain adjacent
to zinc finger domain 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix associated,
actin dependent regulator of
chromatin, subfamily a, member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective inhibitors GSK2801 (pKd 6.6) [73] GSK2801 (pKd 6.9) [73] I-CBP112 (pKd 6.8) [72] PFI-3 (pKd 7.3) [79] PFI-3 (pKd 7.1) [79]
Further reading on Non-enzymatic BRD containing proteins
Brand M et al. (2015) Small molecule inhibitors of bromodomain-acetyl-lysine interactions. ACS
Chem. Biol. 10: 22-39 [PMID:25549280]
Fujisawa T et al. (2017) Functions of bromodomain-containing proteins and their roles in home-
ostasis and cancer Nat Rev Mol Cell Biol 18: 246-262 [PMID:28053347]
Nicholas DA et al. (2017) BET bromodomain proteins and epigenetic regulation of inflamma-
tion: implications for type 2 diabetes and breast cancer. Cell Mol Life Sci 74: 231-243
[PMID:27491296]
Theodoulou NH et al. (2016) Clinical progress and pharmacology of small molecule bromodomain
inhibitors. Curr Opin Chem Biol 33: 58-66 [PMID:27295577]
Theodoulou NH et al. (2016) Progress in the Development of non-BET Bromodomain Chemical
Probes. ChemMedChem 11: 477-87 [PMID:26749027]
Carrier proteins
Other protein targets → Carrier proteins
Overview: Transthyretin (TTR) is a homo-tetrameric protein
which transports thyroxine in the plasma and cerebrospinal fluid
and retinol (vitamin A) in the plasma. Many disease causing
mutations in the protein have been reported, many of which
cause complex dissociation and protein mis-assembly and depo-
sition of toxic aggregates amyloid fibril formation [63]. These
amyloidogenic mutants are linked to the development of patho-
logical amyloidoses, including familial amyloid polyneuropathy
(FAP) [4, 14], familial amyloid cardiomyopathy (FAC) [34], amy-
loidotic vitreous opacities, carpal tunnel syndrome [54] and oth-
ers. In old age, non-mutated TTR can also form pathological
amyloid fibrils [88]. Pharmacological intervention to reduce or
prevent TTR dissociation is being pursued as a theapeutic strat-
egy. To date one small molecule kinetic stabilising molecule
(tafamidis) has been approved for FAP, and is being evaluated in
clinical trials for other TTR amyloidoses.
Nomenclature transthyretin
HGNC, UniProt TTR, P02766
Common abreviation TTR
Searchable database: http://www.guidetopharmacology.org/index.jsp Carrier proteins S8
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Further reading on Carrier proteins
Alshehri B et al. (2015) The diversity of mechanisms influenced by transthyretin in neuro-
biology: development, disease and endocrine disruption. J Neuroendocrinol 27: 303-23
[PMID:25737004]
Delliere S et al. (2017) Is transthyretin a good marker of nutritional status? Clin Nutr 36: 364-370
[PMID:27381508]
Galant NJ et al. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomy-
opathy. Clin Sci (Lond) 131: 395-409 [PMID:28213611]
CD molecules
Other protein targets → CD molecules
Overview: Cluster of differentiation refers to an attempt to catalogue systematically a series of over 300 cell-surface proteins associated with immunotyping. Many members of the group have identified
functions as enzymes (for example, see CD73 ecto-5’-nucleotidase) or receptors (for example, see CD41 integrin, alpha 2b subunit). Many CDs are targetted for therapeutic gain using antibodies for the
treatment of proliferative disorders. A full listing of all the Clusters of Differentiation is not possible in the Guide to PHARMACOLOGY; listed herein are selected members of the family targetted for
therapeutic gain.
Nomenclature CD2 CD3e CD20 (membrane-spanning
4-domains, subfamily A,
member 1)
CD33 CD52
HGNC, UniProt CD2, P06729 CD3E, P07766 MS4A1, P11836 CD33, P20138 CD52, P31358
Common
abreviation
– – – SIGLEC-3 –
Selective inhibitors alefacept (Inhibition)
[17, 53]
– – – –
Antibodies – catumaxomab (Binding)
[43], muromonab-CD3
(Binding) [25],
otelixizumab (Binding) [9]
ofatumumab (Binding) (pKd
9.9) [47], rituximab (Binding)
(pKd 8.5) [75],
ibritumomab tiuxetan (Binding),
obinutuzumab (Binding) [3, 66],
tositumomab (Binding)
lintuzumab (Binding)
(pKd ∼10) [10],
gemtuzumab ozogamicin
(Binding) [7]
alemtuzumab
(Binding) [24, 79]
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S9
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Nomenclature CD80 CD86 cytotoxic T-lymphocyte-associated
protein 4 (CD152)
programmed cell death 1 (CD279) CD300a
HGNC, UniProt CD80, P33681 CD86, P42081 CTLA4, P16410 PDCD1, Q15116 CD300A, Q9UGN4
Common
abreviation
– – CTLA-4 PD-1 –
Antibodies – – ipilimumab (pKd >9) [28],
tremelimumab (pKd 8.9) [30]
pembrolizumab (pKd ∼10) [11], nivolumab
(pKd 9.1) [28, 38, 40]
–
Comment: The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 akaCD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These ligands
are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1 monoclonal
antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. pembrolizumab was the first anti-PD-1 antibody to be
approved by the US FDA.
Further reading on CD molecules
Gabius HJ et al. (2015) The glycobiology of the CD system: a dictionary for translatingmarker desig-
nations into glycan/lectin structure and function. Trends Biochem Sci 40: 360-76 [PMID:25981696]
Methyllysine reader proteins
Other protein targets → Chromatin-interacting transcriptional repressors → Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Nomenclature l(3)mbt-like 3 (Drosophila)
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 [35]
Further reading on Methyllysine reader proteins
Liu K et al. (2015) Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA
methylation. Pharmacol. Ther. 151: 121-40 [PMID:25857453]
Milosevich N et al. (2016) Chemical Inhibitors of Epigenetic Methyllysine Reader Proteins. Bio-
chemistry 55: 1570-83 [PMID:26650180]
Sadakierska-Chudy A et al. (2015) A comprehensive view of the epigenetic landscape part I: DNA
methylation, passive and active DNA demethylation pathways and histone variants. Neurotox
Res 27: 84-97 [PMID:25362550]
Teske KA et al. (2017) Methyllysine binding domains: Structural insight and small molecule probe
development. Eur J Med Chem 136: 14-35 [PMID:28478342]
Zahnow CA et al. (2016) Inhibitors of DNA Methylation, Histone Deacetylation, and Histone
Demethylation: A Perfect Combination for Cancer Therapy. Adv Cancer Res 130: 55-111
[PMID:27037751]
Searchable database: http://www.guidetopharmacology.org/index.jsp Methyllysine reader proteins S10
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Fatty acid-binding proteins
Other protein targets → Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are lowmolecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related metabo-
lites and are usually regarded as being responsible for allowing
the otherwise hydrophobic ligands to be mobile in aqueous me-
dia. These binding proteins may perform functions extracellu-
larly (e.g. in plasma) or transport these agents; to the nucleus
to interact with nuclear receptors (principally PPARs and retinoic
acid receptors [70]) or for interaction with metabolic enzymes.
Although sequence homology is limited, crystallographic stud-
ies suggest conserved 3D structures across the group of binding
proteins.
Nomenclature fatty acid binding protein 1 fatty acid binding protein 2 fatty acid binding protein 3 fatty acid binding protein 4
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090
Rank order of
potency
stearic acid, oleic acid >
palmitic acid, linoleic acid >
arachidonic acid, α-linolenic acid [67]
stearic acid >
palmitic acid,oleic acid >
linoleic acid > arachidonic acid,
α-linolenic acid [67]
stearic acid, oleic acid, palmitic acid
> linoleic acid, α-linolenic acid,
arachidonic acid [67]
oleic acid, palmitic acid,
stearic acid, linoleic acid >
α-linolenic acid, arachidonic acid
[67]
Inhibitors fenofibrate (pKi 7.6) [12] – Rat,
fenofibric acid (pKi 6.5) [12] – Rat,
HTS01037 (pKi 5.1) [30] – Mouse
– – –
Selective inhibitors – – – HM50316 (pKi >9) [46]
Comments A broader substrate specificity than
other FABPs, binding two fatty acids
per protein [82].
Crystal structure of the rat FABP2
[69].
Crystal structure of the human
FABP3 [91].
–
Nomenclature fatty acid binding
protein 5
fatty acid binding
protein 6
fatty acid binding
protein 7
peripheral myelin
protein 2
fatty acid binding
protein 9
fatty acid binding
protein 12
HGNC, UniProt FABP5, Q01469 FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Crystal structure of the
human FABP5 [31].
Able to transport
bile acids [95].
Crystal structure of the
human FABP7 [5].
In silico modelling
suggests that
PMP2/FABP8 can bind
both fatty acids and
cholesterol [50].
– –
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S11
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Nomenclature retinol binding
protein 1
retinol binding protein 2 retinol binding
protein 3
retinol binding protein 4 retinol binding
protein 5
retinol binding
protein 7
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980 RBP7, Q96R05
Rank order of
potency
– stearic acid >
palmitic acid, oleic acid,
linoleic acid,
α-linolenic acid,
arachidonic acid [68]
– – – –
Inhibitors – – – A1120 (pIC50 7.8) [86] – –
Nomenclature retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency 11-cis-retinal, 11-cis-retinol > 9-cis-retinal,
13-cis-retinal, 13-cis-retinol, all-trans-retinal,
retinol [15]
tretinoin > alitretinoin stearic acid >
palmitic acid, oleic acid, linoleic acid,
α-linolenic acid, arachidonic acid [68]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high affinity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [21, 81]. HTS01037 is reported to interfere with FABP4
action [30]. Ibuprofen displays some selectivity for FABP4 (pIC50 5.5) relative to FABP3 (pIC50 3.5) and FABP5 (pIC50 3.8) [48]. Fenofibric acid displays some selectivity for FABP5 (pIC50 5.5) relative to
FABP3 (pIC50 4.5) and FABP4 (pIC50 4.6) [48]. Multiple pseudogenes for the FABPs have been identified in the human genome.
Further reading on Fatty acid-binding proteins
Gajda AM et al. (2015) Enterocyte fatty acid-binding proteins (FABPs): different functions of
liver and intestinal FABPs in the intestine. Prostaglandins Leukot. Essent. Fatty Acids 93: 9-16
[PMID:25458898]
Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot. Essent.
Fatty Acids 93: 45-9 [PMID:25154384]
Hotamisligil GS et al. (2015) Metabolic functions of FABPs-mechanisms and therapeutic implica-
tions. Nat Rev Endocrinol 11: 592-605 [PMID:26260145]
Matsumata M et al. (2016) Fatty acid binding proteins and the nervous system: Their impact on
mental conditions. Neurosci. Res. 102: 47-55 [PMID:25205626]
Osumi T et al. (2016) Heart lipid droplets and lipid droplet-binding proteins: Biochemistry, physi-
ology, and pathology. Exp Cell Res 340: 198-204 [PMID:26524506]
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Notch receptors
Other protein targets → Notch receptors
Overview: The canonocal Notch signalling pathway has four
type I transmembrane Notch receptors (Notch1-4) and five lig-
ands (DLL1, 2 and 3, and Jagged 1-2). Eachmember of this highly
conserved receptor family plays a unique role in cell-fate deter-
mination during embryogenesis, differentiation, tissue pattern-
ing, proliferation and cell death [2]. As the Notch ligands are
also membrane bound, cells have to be in close proximity for
receptor-ligand interactions to occur. Cleavage of the intracel-
lular domain (ICD) of activated Notch receptors by γ-secretase
is required for downstream signalling and Notch-induced tran-
scriptional modulation [18, 57, 71, 89]. This is why γ-secretase
inhibitors can be used to downregulate Notch signalling and
explains their anti-cancer action. One such small molecule is
RO4929097 [47], although development of this compound has
been terminated following an unsuccessful Phase II single agent
clinical trial in metastatic colorectal cancer [78].
Aberrant Notch signalling is implicated in a number of human
cancers [41, 59, 74, 85]. Pharmaceutical inhibitors of Notch sig-
nalling such as demcizumab and tarextumab are being actively
investigated as novel anti-cancer agents [64].
Nomenclature notch 1 notch 2 notch 3 notch 4
HGNC, UniProt NOTCH1, P46531 NOTCH2, Q04721 NOTCH3, Q9UM47 NOTCH4, Q99466
Comments Various types of activating and inactivating NOTCH1 mutations have been
reported to be associated with human diseases, for example: aortic valve
disease [23, 52], Adams-Oliver syndrome 5 [76], T-cell acute lymphoblastic
leukemia (T-ALL) [87], chronic lymphocytic leukemia (CLL) [65] and head and
neck squamous cell carcinoma [1, 77].
– – Notch 4 is a potential
therapeutic molecular
target for triple-negative
breast cancer [42, 55].
Further reading on Notch receptors
Borggrefe T et al. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog,
TGFbeta/BMP and hypoxia pathways. Biochim Biophys Acta 1863: 303-313 [PMID:26592459]
Cheng YL et al. (2015) Emerging roles of the gamma-secretase-notch axis in inflammation. Phar-
macol Ther 147: 80-90 [PMID:25448038]
Palmer WH et al. (2015) Ligand-Independent Mechanisms of Notch Activity. Trends Cell Biol 25:
697-707 [PMID:26437585]
Previs RA et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch
signaling pathway in cancer. Clin Cancer Res 21: 955-61 [PMID:25388163]
Takebe N et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical
update. Nat Rev Clin Oncol 12: 445-464 [PMID:25850553]
Regulators of G protein Signaling (RGS) proteins
Other protein targets → Regulators of G protein Signaling (RGS) proteins
Overview: Regulators of G protein signalling (RGS) proteins increase the deactivation rates of G protein signalling pathways through enhancing the GTPase activity of the G protein alpha subunit.
Interactions through protein:protein interactions of many RGS proteins have been identified for targets other than heteromeric G proteins. The 20 RGS proteins are commonly divided into four families
(R4, R7, R12 and RZ) based on sequence and domain homology. Described here is RGS4 for which a number of pharmacological inhibitors have been described.
Searchable database: http://www.guidetopharmacology.org/index.jsp Regulators of G protein Signaling (RGS) proteins S13
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Nomenclature regulator of G-protein signaling 4
HGNC, UniProt RGS4, P49798
Common abreviation RGS4
Selective inhibitors RGS4 inhibitor 11b (pIC50 7.8) [83], CCG-50014 (pIC50 7.5) [8, 83], RGS4 inhibitor 13 (pIC50 7.3) [83]
Further reading on RGS proteins
Sethakorn N et al. (2010) Non-canonical functions of RGS proteins. Cell Signal 22: 1274-81
[PMID:20363320]
Sjogren B (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br J Pharmacol 174: 427-437 [PMID:28098342]
Sjogren B et al. (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting
of regulators of G protein signaling. Mol Pharmacol 78: 550-7 [PMID:20664002]
Turner EM et al. (2012) Small Molecule Inhibitors of Regulator of G Protein Signalling (RGS) Pro-
teins. ACS Med Chem Lett 3: 146-150 [PMID:22368763]
Sigma receptors
Other protein targets → Sigma receptors
Overview: Although termed ‘receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors; the crystal structure of the sigma1 receptor [94] suggests a trimeric structure of a single short transmembrane
domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been
observed to bind to these sites.
Nomenclature sigma non-opioid intracellular receptor 1 σ2
HGNC, UniProt SIGMAR1, Q99720 –
Selective agonists PRE-084 [80], (+)-SKF 10.047 –
Selective antagonists NE-100 (pIC50 8.4) [60], BD-1047 (pIC50 7.4) [51] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments: (-)-pentazocine also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be TMEM97 Q5BJF2 [92] , a 4TM protein partner of NPC1, the Niemann-Pick C1
protein, a 13TM cholesterol-binding protein.
Further reading on Sigma receptors
ChuUB et al. (2016) Biochemical Pharmacology of the Sigma-1 Receptor. Mol Pharmacol 89: 142-53
[PMID:26560551]
Gris G et al. (2015) Sigma-1 receptor and inflammatory pain. Inflamm Res 64: 377-81
[PMID:25902777]
Rousseaux CG et al. (2015) Sigma receptors [sigmaRs]: biology in normal and diseased states. J
Recept Signal Transduct Res 1-62 [PMID:26056947]
Su TP et al. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends
Pharmacol Sci 37: 262-78 [PMID:26869505]
van Waarde A et al. (2015) Potential applications for sigma receptor ligands in cancer diagnosis
and therapy. Biochim Biophys Acta 1848: 2703-14 [PMID:25173780]
Searchable database: http://www.guidetopharmacology.org/index.jsp Sigma receptors S14
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Tubulins
Other protein targets → Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Nomenclature tubulin
alpha 1a
tubulin
alpha 4a
tubulin beta class I tubulin beta 3
class III
tubulin beta 4B
class IVb
tubulin beta 8
class VIII
HGNC,
UniProt
TUBA1A,
Q71U36
TUBA4A,
P68366
TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), vincristine, eribulin (pIC50 8.2)
[58], paclitaxel (pEC50 8.1) [61], colchicine (pIC50 8)
[13], cabazitaxel, docetaxel, ixabepilone
combretastatin A4
(pIC50 8.2) [22]
– –
Further reading on Tubulins
Gadadhar S et al. (2017) The tubulin code at a glance. J Cell Sci 130: 1347-1353 [PMID:28325758] Penna LS et al. (2017) Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Pharmacol Ther 173: 67-82 [PMID:28174095]
Searchable database: http://www.guidetopharmacology.org/index.jsp Tubulins S15
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